The cardiovascular effects of GLP-1 receptor agonists - PubMed (original) (raw)

Review

The cardiovascular effects of GLP-1 receptor agonists

Theodore Okerson et al. Cardiovasc Ther. 2012 Jun.

Free PMC article

Abstract

Glucagon-like peptide-1 receptor (GLP-1R) agonists have been shown to regulate blood glucose concentrations by mechanisms including enhanced insulin synthesis/secretion, suppressed glucagon secretion, slowed gastric emptying, and enhanced satiety. GLP-1 receptors have also been identified in the heart, kidneys, and blood vessels, leading to the hypothesis that GLP-1R agonists may affect cardiovascular function or cardiovascular disease (CVD). The aim of this literature review was to assemble and assess preclinical and clinical data of potential medical importance regarding the cardiovascular effects of GLP-1R agonists. Preclinical studies with the GLP-1R agonists GLP-1, exenatide, or liraglutide provided evidence that GLP-1R stimulation favorably affects endothelial function, sodium excretion, recovery from ischemic injury, and myocardial function in animals. Similar observations have been made in exploratory studies on GLP-1 infusion in normal subjects and patients with type 2 diabetes. Post hoc analyses of phase III studies of patients with type 2 diabetes treated with exenatide(bid or qw) or liraglutide(qd) showed that these GLP-1R agonists reduced blood pressure, an effect largely independent of weight loss, and that liraglutide slightly increased heart rate. Preliminary data also indicated that GLP-1R agonists reduced markers of CVD risk such as C-reactive protein and plasminogen activator inhibitor-1. Ongoing studies are examining the effects of administering GLP-1R agonists to patients at risk of CVD, postangioplasty patients, post-CABG patients, and patients with heart failure. Additional studies should provide meaningful data to determine whether GLP-1R agonists provide unique treatment benefits to patients at risk for or with established CVD.

© 2010 Blackwell Publishing Ltd.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Nongastrointestinal GLP-1R. (A) Overview of organs and tissues with GLP-1R. (B) Quantitation of GLP-1R expression in mouse tissues. (C) Immunohistochemical staining (green) demonstrating localization of GLP-1R in the endocardium (B, C reproduced with permission from [22]).

Figure 2

Figure 2

Schematic of GLP-1R signaling in heart cells. (A) Intracellular signaling. (B) Vascular consequences of GLP-1R signaling [22].

Figure 3

Figure 3

Systolic blood pressure (SBP) changes from baseline-to-endpoint (6 months) in patients with T2DM treated with exenatide (mean ± SE). (A) Exenatide versus placebo. (B) Exenatide versus insulin (Reprinted from [63]).

Similar articles

Cited by

References

    1. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA. 2007;298:194–206. [See the comment] - PubMed
    1. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705. [See the comment] - PubMed
    1. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405–412. [See the comment] - PMC - PubMed
    1. Look ARG, Pi-Sunyer X, Blackburn G, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: One-year results of the look AHEAD trial. Diabet Care. 2007;30:1374–1383. [See the comment] - PMC - PubMed
    1. Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: An observational study in 13,087 patients. Diabetologia. 2009;52:65–73. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources